Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself-Reference-Cited by-同舟云学术

Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself

Published:2015-02-17 Issue:2 Volume:10 Page:e0118187
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

McCrudden Cian M.,O’Rourke Martin G.,Cherry Kim E.,Yuen Hiu-Fung,O’Rourke Declan,Babur Muhammad,Telfer Brian A.,Thomas Huw D.,Keane Patrick,Nambirajan Thiagarajan,Hagan Chris,O’Sullivan Joe M.,Shaw Chris,Williams Kaye J.,Curtin Nicola J.,Hirst David G.,Robson Tracy

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. The role of poly(ADP-ribosyl)ation in epigenetic events;D Quenet;Int J Biochem Cell Biol,2009

2. Poly(ADP-ribose): novel functions for an old molecule;V Schreiber;Nat Rev Mol Cell Biol,2006

3. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond;NJ Curtin;Mol Aspects Med,2013

4. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors;DJ Skalitzky;J Med Chem,2003

5. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361;CR Calabrese;J Natl Cancer Inst,2004

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite;Cell Chemical Biology;2024-05

2. Identification of differential polypharmacology between the PARP inhibitor rucaparib and its major metabolite;2022-11-24

3. CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration;BMC Urology;2022-09-21

4. High S100A7 expression is associated with early muscle invasion and poor survival in bladder carcinoma;Annals of Diagnostic Pathology;2022-02

5. Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases;Antioxidants;2021-12-03